AU2016212625B2 - Prevention or treatment of uric acid or gout disease - Google Patents
Prevention or treatment of uric acid or gout disease Download PDFInfo
- Publication number
- AU2016212625B2 AU2016212625B2 AU2016212625A AU2016212625A AU2016212625B2 AU 2016212625 B2 AU2016212625 B2 AU 2016212625B2 AU 2016212625 A AU2016212625 A AU 2016212625A AU 2016212625 A AU2016212625 A AU 2016212625A AU 2016212625 B2 AU2016212625 B2 AU 2016212625B2
- Authority
- AU
- Australia
- Prior art keywords
- purine
- dione
- chloro
- uric acid
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *c1nc(NC(N(*)C2=C)=O)c2[n]1 Chemical compound *c1nc(NC(N(*)C2=C)=O)c2[n]1 0.000 description 2
- KOZZYIHVPUEIPB-UHFFFAOYSA-N C=CC[n]1c(Cl)nc(NC(N2)=O)c1C2=O Chemical compound C=CC[n]1c(Cl)nc(NC(N2)=O)c1C2=O KOZZYIHVPUEIPB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510048096 | 2015-01-30 | ||
| CN201510048096.3 | 2015-01-30 | ||
| CN201510080714 | 2015-02-13 | ||
| CN201510079809.2 | 2015-02-13 | ||
| CN201510080714.2 | 2015-02-13 | ||
| CN201510079809 | 2015-02-13 | ||
| CN201510216089 | 2015-04-30 | ||
| CN201510216089.X | 2015-04-30 | ||
| PCT/CN2016/000061 WO2016119570A1 (zh) | 2015-01-30 | 2016-01-28 | 尿酸性或痛风性疾病的预防或治疗 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2016212625A1 AU2016212625A1 (en) | 2017-07-27 |
| AU2016212625B2 true AU2016212625B2 (en) | 2020-03-26 |
Family
ID=56542370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016212625A Active AU2016212625B2 (en) | 2015-01-30 | 2016-01-28 | Prevention or treatment of uric acid or gout disease |
Country Status (26)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12566174B2 (en) | 2017-05-11 | 2026-03-03 | The Research Foundation For The State University Of New York | Method and kit for determining the presence of monosodium urate crystals in joint synovial fluid |
| AU2024229006A1 (en) | 2023-02-27 | 2025-09-18 | Shanton Pharma Pte. Ltd. | Crystal form of 8-chloro-3-pentyl-3,7-dihydro-1h-purin-2,6-dione compound and preparation method therefor |
| CN116650490B (zh) * | 2023-06-07 | 2025-05-20 | 中国人民解放军海军军医大学 | 化合物mt-1207在降低尿酸方面的应用 |
| EP4497439A1 (en) * | 2023-07-28 | 2025-01-29 | Universitat de les Illes Balears | Compounds for the treatment or prevention of gout |
| TWI902254B (zh) * | 2024-05-16 | 2025-10-21 | 新加坡商珊頓醫藥科技新加坡公司 | 化合物8-氯-3-戊基-3,7-二氫-1h-嘌呤-2,6-二酮的晶型及其製備方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993016699A1 (en) * | 1992-02-21 | 1993-09-02 | Smithkline Beecham Corporation | Tnf inhibitors |
| WO2005077950A2 (en) * | 2004-02-14 | 2005-08-25 | Smithkline Beecham Corporation | Medicaments with hm74a receptor activity |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8906792D0 (en) | 1989-03-23 | 1989-05-10 | Beecham Wuelfing Gmbh & Co Kg | Treatment and compounds |
| AR015966A1 (es) | 1997-10-17 | 2001-05-30 | Smithkline Beecham Corp | Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito |
| AR061626A1 (es) * | 2006-06-23 | 2008-09-10 | Incyte Corp | Derivados de purinona como agonistas de hm74a |
| CN101479273B (zh) | 2006-06-23 | 2011-11-30 | 英赛特股份有限公司 | 作为hm74a激动剂的嘌呤酮衍生物 |
| WO2010071865A1 (en) * | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
| US20110136835A1 (en) * | 2009-09-14 | 2011-06-09 | Nuon Therapeutics, Inc. | Combination formulations of tranilast and allopurinol and methods related thereto |
| WO2011057110A1 (en) | 2009-11-06 | 2011-05-12 | Ruprecht-Karls-Universitat-Heidelberg | Gpr109a agonists for the treatment of cerebral ischemia |
-
2016
- 2016-01-28 PT PT167426329T patent/PT3251675T/pt unknown
- 2016-01-28 KR KR1020177024392A patent/KR102128810B1/ko active Active
- 2016-01-28 HR HRP20211007TT patent/HRP20211007T1/hr unknown
- 2016-01-28 SG SG11201705889VA patent/SG11201705889VA/en unknown
- 2016-01-28 PL PL16742632T patent/PL3251675T3/pl unknown
- 2016-01-28 HU HUE16742632A patent/HUE054741T2/hu unknown
- 2016-01-28 SG SG10201907026RA patent/SG10201907026RA/en unknown
- 2016-01-28 MX MX2017009853A patent/MX380301B/es unknown
- 2016-01-28 CA CA2973746A patent/CA2973746C/en active Active
- 2016-01-28 BR BR112017016065-0A patent/BR112017016065A2/pt not_active Application Discontinuation
- 2016-01-28 MA MA41431A patent/MA41431B1/fr unknown
- 2016-01-28 SM SM20210359T patent/SMT202100359T1/it unknown
- 2016-01-28 WO PCT/CN2016/000061 patent/WO2016119570A1/zh not_active Ceased
- 2016-01-28 ES ES16742632T patent/ES2881872T3/es active Active
- 2016-01-28 EP EP16742632.9A patent/EP3251675B1/en active Active
- 2016-01-28 DK DK16742632.9T patent/DK3251675T3/da active
- 2016-01-28 LT LTEP16742632.9T patent/LT3251675T/lt unknown
- 2016-01-28 EA EA201791714A patent/EA034139B1/ru unknown
- 2016-01-28 AU AU2016212625A patent/AU2016212625B2/en active Active
- 2016-01-28 JP JP2017558605A patent/JP6678685B2/ja active Active
- 2016-01-28 SI SI201631264T patent/SI3251675T1/sl unknown
- 2016-01-28 US US15/512,412 patent/US10322132B2/en active Active
- 2016-01-28 CN CN201680001581.8A patent/CN107206002B/zh active Active
- 2016-01-29 TW TW105102935A patent/TWI680761B/zh active
-
2017
- 2017-07-07 ZA ZA2017/04600A patent/ZA201704600B/en unknown
- 2017-07-30 IL IL253726A patent/IL253726B2/en unknown
-
2021
- 2021-06-22 CY CY20211100551T patent/CY1124383T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993016699A1 (en) * | 1992-02-21 | 1993-09-02 | Smithkline Beecham Corporation | Tnf inhibitors |
| WO2005077950A2 (en) * | 2004-02-14 | 2005-08-25 | Smithkline Beecham Corporation | Medicaments with hm74a receptor activity |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2973746C (en) | Prevention or treatment of uratic or gouty diseases | |
| CN108042542A (zh) | 用于治疗病症的方法和组合物 | |
| CN111662281B (zh) | 水杨酸类小檗碱型生物碱季铵盐及其制备药物的用途 | |
| EP3027183B1 (en) | Selective at2 receptor agonists for use in treatment of cachexia | |
| CN103608014A (zh) | 激酶抑制剂在治疗和预防炎症疾病中的用途 | |
| KR102418211B1 (ko) | 일시적 수용체 전위 a1 이온 채널의 억제 | |
| CN101250183A (zh) | 一种雷贝拉唑的光学异构体及其制备方法、医药用途 | |
| HK1199250A1 (en) | Biaryl heterocycle substituted oxazolidinon antibacterial drug | |
| CN111093661A (zh) | 戊二酰亚胺衍生物用于治疗与细胞因子的异常活性相关的疾病的用途 | |
| CN100486574C (zh) | 用于神经系统疾病的治疗和/或预防药物 | |
| CN114671878B (zh) | 取代的含氮双环化合物及其用途 | |
| HK1245146B (en) | Prevention or treatment of uric acid or gout disease | |
| EP2980087B1 (en) | Prodrugs of bicyclic substituted pyrimidine type pde-5 inhibitors | |
| JP2022188199A (ja) | Ｇｐｒ６のテトラヒドロピリドピラジンモジュレーター | |
| US20070004777A1 (en) | Methods for treating or preventing acute myelogenous leukemia | |
| HK1244434B (en) | Prevention or treatment of uric acid or gout disease | |
| JP2022532186A (ja) | 非晶質のｐｉ３ｋ阻害剤及びこれを含有する医薬組成物 | |
| WO2014158302A1 (en) | Novel sphingosine 1-phosphate receptor antagonists | |
| CN111303161B (zh) | 嘧啶并氮杂环类化合物及其用途 | |
| KR20090100443A (ko) | 심혈관 질환 치료용 1,3-디히드로이미다졸 | |
| TW201022254A (en) | S1P lyase inhibitors for the treatment of cerebral malaria | |
| WO2025255840A1 (zh) | 治疗患者的中至重度活动性类风湿关节炎的方法 | |
| CN117500506A (zh) | Atr抑制剂与parp抑制剂的组合用于治疗癌症的用途 | |
| HK40028225A (en) | Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines | |
| JPH0739423B2 (ja) | ピリミドベンゾチアジン誘導体を含む抗炎症剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| PC | Assignment registered |
Owner name: SHANTON PHARMA PTE. LTD. Free format text: FORMER OWNER(S): SHANTON PHARMA CO., LTD. |